Advisory Board

Dr. Gary S. Mezo

The Nanotechnology Business article Interview with Dr. Gary Mezo said

Question 1: Tell us about how and when nanobacteria were discovered: Our colleagues and Nobel Prize Nominee Medical Researchers, Neva Ciftcioglu, PhD and Olavi Kajander, MD, PhD, (Microbiology Department-University of Kuopio, Finland) were working on several medical research projects in 1992 using mammalian cell cultures. They became frustrated because their mammalian cell cultures kept dying. Mammalian cell cultures and most all human biologicals are normally grown in fetal bovine serum (FBS) and cell culture death is a common problem in medical research that forces researchers to start entire projects over again and again.
 
Well, this time instead of just discarding the dead mammalian cell cultures, they just left them in the incubator and subsequently forgot about them. Approximately four months later finding the old cultures, they realized that an unusual thin slimy film had developed on the culture surfaces. Well, since scientists are by nature as inquisitive as cats, Drs. Ciftcioglu and Kajander they couldn’t resist full evaluation of this unusual slime. They were not able to determine the nature of the film using the highest power light microscopes, so they used Scanning Electron Microscopes and Transmission Electron Microscopes from lowest to highest magnification (100,000X).
 
Lo and behold! They found these 20–200 nanometer sized nanobacteria in calcified shells: The bacteria in the stone! They had never seen anything like them, and nothing like them had ever been seen or described in the microbiology world. These nanobacteria are structurally and physiologically unique in many ways: they are 20–200 nanometers in size, they have a unique “cellular” structure and membrane structure like nothing else on earth, they replicate very slowly (every 3–5 days) and by different methods, they are pleomorphic meaning that they assume different life forms for different phases and activities of their lives, they can go dormant in a self-made calcium shell, they are saprophytic in humans, they are “the toughest of bugs” — resistant to being killed both In-Vitro and In-Vivo and they are the cause of many human diseases.
 
They are structurally and functionally simplistic, unbelievably small and genetically unique. Although nicked-named by one reporter as “Conan the Bacterium”, Drs. Ciftcioglu & Kajander formally named this novel pleomorphic nanobacteria that thrives in our blood, Nanobacterium sanguineum.

Gary S. Mezo, PhD, ARNP, PAC is Chairman & CEO at NanoBiotech and is the Founder and Retired Chairman/CEO of Nanobac Pharmaceuticals, Inc. (OTC: NNBP).
 
Gary focuses on Degenerative Diseases & Regenerative Medicine. As we can see so far, most degenerative disease states are related in one way or another to chronic inflammation and/or pathological calcification. The last decade of work has been to develop methodologies that halt progression of many degenerative diseases and to reverse pathology. His research teams have been successful in many areas and the results thus far have been rewarding and remain extremely promising.
 
His specialities are Nanobacterial Research, Diagnostics & Pharmaceutical Product Development, Anti-aging methodologies, Endovascular disease research, Chronic degenerative disease therapeutics & management, Regenerative Medicine, Neuro-degenerative disorders: MS, ALS, Parkinson’s & Alzheimer’s, and Systemic Lupus Erythematosis (SLE).
 
Gary is Founder of the Academy of Medical Nanoscience (AMN) and member of American College of Cardiology (ACC), American Heart Association (AHA), American Society for Microbiology (ASM), American Association for the Advancement of Science (AAAS), American Academy of Anti-Aging Medicine (A4M), Association for the Eradication of Heart Attack (AHEA), Society for Heart Attack Prevention & Eradication (SHAPE), AAPA, IAPA, AANP, BBV, Alpha Kappa Psi, Tampa Club, and Citrus Club. He is Director of the Central Florida Ballet.